ChemicalBook--->CAS DataBase List--->1029712-80-8

1029712-80-8

1029712-80-8 Structure

1029712-80-8 Structure
IdentificationBack Directory
[Name]

INCB28060
[CAS]

1029712-80-8
[Synonyms]

NC280
INC280
CS-192
INC28060
INCB28060
NVP-INC280
INCB028060
CapMatinib
BenzaMide HCl
Capmatinib base
INCB28060, INC280
INC280 Capmatinib
CAPMATINIB (INC280)
BenzaMide INCB28060
INC 280 (INCB28060)
INCB28060,BenzaMide
Capmatinib USP/EP/BP
INCB28060(Capmatinib)
CapMatinib (INCB28060)
INCB 28060; INCB-28060; INC280
CAPMATINIB (INCB28060);INCB-28060; INC-280
2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
2-Fluoro-N-Methyl-4-(7-quinolin-6-ylMethyl-iMidazo[1,2-b][1,2,4] triazin-2-yl)-benzaMide
BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-
NC280 BenzaMide,2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-
BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]- INCB28060
INC28060(BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-)
2-fluoro-n-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide capmatinib
2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide Capmatinib (INCB28060)
[EINECS(EC#)]

813-241-9
[Molecular Formula]

C23H17FN6O
[MDL Number]

MFCD18633285
[MOL File]

1029712-80-8.mol
[Molecular Weight]

412.419
Chemical PropertiesBack Directory
[Melting point ]

>250°C (dec.)
[density ]

1.40
[vapor pressure ]

0-0Pa at 20-25℃
[storage temp. ]

-20°C Freezer, Under inert atmosphere
[solubility ]

DMSO (Slightly), Methanol (Slightly)
[form ]

Solid
[pka]

13.82±0.46(Predicted)
[color ]

Pale Yellow to Light Yellow
[InChI]

InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
[InChIKey]

LIOLIMKSCNQPLV-UHFFFAOYSA-N
[SMILES]

C(NC)(=O)C1=CC=C(C2=NN3C(CC4=CC=C5C(=C4)C=CC=N5)=CN=C3N=C2)C=C1F
[LogP]

1.6-2.2 at 35℃ and pH7-9
Safety DataBack Directory
[Symbol(GHS) ]

Exclamation Mark (GHS07)
GHS07
[Signal word ]

Warning
[Hazard statements ]

H302-H315-H319-H335
[Precautionary statements ]

P261-P305+P351+P338
[REACH Registrations]

Active
Questions And AnswerBack Directory
[MET small molecule inhibitor]

Capmatinib(Synonyms: INC280; INCB28060) is a competitive inhibitor with very potent and selective activity against MET compared to other kinases. It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day. Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels.
[Originator]

Novartis
Hazard InformationBack Directory
[Description]

Capmatinib is a competitive inhibitor with very potent and selective activity against MET compared to other kinases.
[Uses]

2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide is used in the preparation of a combination formulation with allosteric SHP2 inhibitor TNO155. Used in treatment of non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
[Brand name]

Tabrecta
[General Description]

Class: receptor tyrosine kinase; Treatment: NSCLC with METex14; Other name: INCB28060; Oral bioavailability >70%; Elimination half-life = 7.8 h; Protein binding = 96%
[Side effects]

Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels.
[Synthesis]

2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoicacid

1029714-88-2

Methylamine

74-89-5

Capmatinib

1029712-80-8

Example 20 Synthesis of 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide (15): 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoic acid (14, 331.4 g, 0.914 mol, 1.0 eq.) and (benzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate (PyBOP, 570 g, 1.1 mol, 1.2 eq.) were dissolved in N,N-dimethylformamide (DMF, 3700 mL). To this solution, a tetrahydrofuran solution of 2M methylamine (1830 mL, 3.656 mol, 4.0 eq.) was slowly added for 15 min at room temperature. The reaction temperature was raised to 30 °C during the addition and the reaction mixture became homogeneous. Subsequently, triethylamine (TEA, 382 mL, 2.742 mol, 3.0 eq.) was added to the reaction mixture and the reaction mixture was stirred for 2-4 h at room temperature. The progress of the reaction was monitored by LC/MS and after confirming the completion of the coupling reaction, water (950 mL) was added to the reaction mixture. The resulting suspension was cooled to 0-5 °C in an ice bath and stirred at this temperature for 30 min. The solid was collected by filtration and washed with water (200 mL). The wet solid filter cake was suspended in a solvent mixture of water and acetonitrile (1:1 v/v, 2000 mL) and stirred for 1 hour at room temperature. The solid was collected by filtration, washed sequentially with water and acetonitrile, and then dried to constant weight in a vacuum oven at 40-45 °C to afford 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide (15, 322 g, 85.4% yield) as a yellow to bright yellow powder.

[in vitro]

It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day.
[target]

c-MET
[Dosage]

The recommended capmatinib dose is 400 mg orally twice daily with or without food.
[References]

1. liu x, wang q, yang g, et al. a novel kinase inhibitor, incb28060, blocks c-met-dependent signaling, neoplastic activities, and cross-talk with egfr and her-3. clinical cancer research : an official journal of the american association for cancer research. 2011;17(22):7127-7138.
Spectrum DetailBack Directory
[Spectrum Detail]

Capmatinib(1029712-80-8)1HNMR
1029712-80-8 suppliers list
Company Name: Tianjin Zhongcheng Mingyuan Technology Co., Ltd.  Gold
Telephone: 13302022156
Website: https://www.chemicalbook.com/ShowSupplierProductsList30619/0_EN.htm
Company Name: Suzhou Ryan Pharmaceutical Technology Co., Ltd.  Gold
Telephone: 0512-68780025 18962125825
Website: http://www.ryanchem.com
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Telephone:
Website: www.boylechem.com
Company Name: Chembest Research Laboratories Limited  
Telephone: 021-20908456
Website: www.biochembest.com
Company Name: Jinan Trio PharmaTech Co., Ltd.  
Telephone: 0531-88811783
Website: www.trio-pharmatech.com
Company Name: Dalian Meilun Biotech Co., Ltd.  
Telephone: 0411-62910999 13889544652
Website: http://www.meilunbio.com/
Company Name: T&W GROUP  
Telephone: 021-61551611 13296011611
Website: www.trustwe.com/
Company Name: Shanghai Topbiochem Technology Co., Ltd  
Telephone: 021-58170097
Website: www.topbiochem.com
Company Name: NCE Biomedical Co.,Ltd.  
Telephone: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Website: www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm
Company Name: Haoyuan Chemexpress Co., Ltd.  
Telephone: 021-58950125
Website: http://www.chemexpress.com.cn
Company Name: Shanghai Aladdin Bio-Chem Technology Co.,LTD  
Telephone: 400-6206333 13167063860
Website: www.aladdin-e.com/
Company Name: ExcelChemical (Shanghai) Chemical Technology Co., Ltd.  
Telephone: +86 13671938079
Website: www.chemicalbook.com/ShowSupplierProductsList15847/0_EN.htm
Company Name: Moltt Biocem Co., Ltd.  
Telephone: +86-21-38682181 15900741819
Website: www.chemicalbook.com/ShowSupplierProductsList15856/0_EN.htm
Company Name: Shanghai Witofly Chemical Co.,Ltd  
Telephone:
Website: www.witofly.com
Company Name: Guangzhou Isun Pharmaceutical Co., Ltd  
Telephone: 020-39119399 18927568969
Website: http://www.isunpharm.com
Company Name: Nanjing Sunlida Biological Technology Co., Ltd.  
Telephone: 025-57798810 18652991625
Website:
Company Name: TargetMol Chemicals Inc.  
Telephone: 021-021-33632979 15002134094
Website: https://www.targetmol.cn/
Company Name: Jinan Mingya Medical Technology Co., Ltd.  
Telephone: 0531-85828981
Website: www.chemicalbook.com/ShowSupplierProductsList16067/0_EN.htm
Tags:1029712-80-8 Related Product Information
877399-52-5 1022150-57-7 302962-49-8 1116235-97-2 606143-52-6 1032900-25-6 443913-73-3 439081-18-2 417716-92-8 1197958-12-5 1110813-31-4 1195765-45-7 1213269-23-8 849217-68-1 1197376-85-4 1202777-78-3 1454846-35-5